🇺🇸 FDA
Pipeline program

QTORIN 3.9% Rapamycin Anhydrous Gel

PALV-09

Phase 3 small_molecule active

Quick answer

QTORIN 3.9% Rapamycin Anhydrous Gel for Microcystic Lymphatic Malformation is a Phase 3 program (small_molecule) at PALVELLA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PALVELLA THERAPEUTICS, INC.
Indication
Microcystic Lymphatic Malformation
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials